Sofituzumab vedotin
Sofituzumab Vedotin
Sofituzumab Vedotin (pronunciation: so-fi-tu-zu-mab ve-do-tin) is a monoclonal antibody-drug conjugate used in the treatment of certain types of cancer.
Etymology
The name "Sofituzumab Vedotin" is derived from the combination of "Sofituzumab", a monoclonal antibody, and "Vedotin", a cytotoxic drug. The term "Sofituzumab" is a combination of "sofi", a prefix used in pharmaceutical nomenclature to denote a specific type of monoclonal antibody, and "tuzumab", a suffix used in pharmaceutical nomenclature to denote humanized antibodies. "Vedotin" is a term used to denote a specific type of cytotoxic drug.
Usage
Sofituzumab Vedotin is used in the treatment of certain types of cancer, including non-small cell lung cancer and ovarian cancer. It works by binding to a specific protein on the surface of cancer cells and delivering a cytotoxic drug directly to the cells, causing them to die.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Cytotoxic drug: A type of medication that kills cells, especially cancer cells.
- Non-small cell lung cancer: A type of lung cancer that is often treated with Sofituzumab Vedotin.
- Ovarian cancer: A type of cancer that begins in the ovaries, which are female reproductive glands that produce eggs.
External links
- Medical encyclopedia article on Sofituzumab vedotin
- Wikipedia's article - Sofituzumab vedotin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski